Turn Therapeutics Inc.
TTRXHealthcare|Biotechnology|US
$9.48
+0.54 (+6.04%)
DCF Value
$0.18
Cash / Share
$0.35
Clinical Trials (3)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06672887 Enhancing Successful Return to Work of Employees With Cancer, by Supporting Employers (MiLES Intervention) | Cancer, Neoplasm | P2P3 | Recruiting | 140 | RCT, Single-blind | — |
| NCT07355075 A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) | Eczema Atopic Dermatitis, Eczema | P2P3 | Recruiting | 190 | RCT, Double-blind | — |
| NCT04951349 Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19. | Covid19 | P2 | Completed | 85 | RCT, Double-blind | GX-03, Petrolatum ointment |